Virobay
Hepatitis is an inflammation of the liver mainly induced by autoimmunity, chemical or infectious agents. In the United States, the third most prevalent form of chronic infections is caused by hepatitis C virus (HCV). Worldwide there are an estimated 170 million people infected with HCV with nearly 4 million infected individuals in the United States.
Hepatitis C Protease Inhibitors: VBY-376 and VBY-106
Virobay is developing VBY-376 as a therapeutic agent for HCV infection. VBY-376 blocks viral replication through the specific inhibition of the HCV NS3/4A protease, a target that has been proven through genetic validation and clinical trials to be essential for HCV replication.
VBY-376 is highly selective protease inhibitor and exhibits potent antiviral activity in cellular models. VBY-376 represents a potential therapeutic agent with a different mechanism of action than the current standard of care of pegylated interferon and ribavirin. VBY-376 has completed single ascending dose Phase I clinical trial.
As a result of ongoing medicinal chemistry and selective biological screening methods, Virobay has identified a second protease inhibitor with 10 fold greater potency in a cell based assay. This compound, VBY-106, has entered Phase 0 (clinical candidate) evaluation activities.
Based on preclinical pharmacokinetic modeling, once-daily and twice-daily dosing frequencies will be evaluated in clinical trials.
Request Further Information:
Hepatitis C Protease Inhibitors